This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gass, E. K. Articles by Edwards, D. P. Search for Related Content PubMed PubMed Citation Articles by Gass, E. K. Articles by Edwards, D. P.

The Antagonists RU486 and ZK98299 Stimulate Progesterone Receptor Binding to Deoxyribonucleic Acid in Vitro and in Vivo, but Have Distinct Effects on Receptor Conformation¹

Department of Pathology (E.K.G., S.A.L., S.K.N., D.P.E.) and Molecular Biology Program S.K.N. D.P.E.), University of Colorado Health Sciences Center, Denver, Colorado 80262

Address all correspondence and requests for reprints to: Dr. Dean P. Edwards, Department of Pathology and Molecular Biology Program, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, Colorado 80262. E-mail: edwards_d{at}defiance.uchsc.edu

Three types of transfection experiments were used to detect the abilities of different classes of antagonists to stimulate binding of progesterone receptor (PR) to progesterone response elements (PRE) in intact mammalian cells. These included a promoter interference assay, in which PR binding to PREs positioned between the TATA box and the start of transcription is detected as a reduction of expression of a constitutively active reporter gene, competition of PR antagonist and glucocorticoid receptor agonist for a common glucocorticoid response element/PRE-controlled reporter construct, and activation of a chimeric receptor (PR-VP16) containing the constitutive trans-activation domain derived from the VP16 protein of herpes simplex virus. By each approach, all antagonists tested were equally effective in stimulating PR binding to PREs in the cell. This included previously designated type I (ZK98299) and type II (RU486, ZK98734, and ZK112993) 11ß-aryl substituted steroid analogs. Stimulation of PR binding to PREs in the cell by ZK98299 was of interest because this antagonist has been reported to lack the ability to stimulate PR-DNA binding in vitro by electrophoretic gel mobility shift assay compared with RU486, which promotes efficient binding of PR to PREs. To clarify the apparent discrepancy between intact cell and in vitro results with ZK98299, we altered electrophoretic gel mobility shift assay conditions to allow detection of less stable DNA complexes. Under these conditions, ZK98299 induced the formation of specific PR-PRE complexes. Further analysis of the ZK98299-induced DNA complexes revealed that they exhibited an electrophoretic mobility different from that of the complexes induced by RU486, and the off-rate of PR from DNA was faster than that of the PR bound to agonist. This suggests that ZK98299 promotes a conformational change within PR distinct from that induced by RU486. The present results are consistent with the conclusions that ZK98299 stimulates PR binding to target DNA sequences and that ZK98299 and RU486 represent two mechanistic classes of antagonists based on inducing different conformational changes in PR.

This article has been cited by other articles:

				N. Z. Lu, S. E. Wardell, K. L. Burnstein, D. Defranco, P. J. Fuller, V. Giguere, R. B. Hochberg, L. McKay, J.-M. Renoir, N. L. Weigel, et al. International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors Pharmacol. Rev., December 1, 2006; 58(4): 782 - 797. [Full Text] [PDF]

				Z.-Y. Zheng, B.-H. Bay, S.-E. Aw, and V. C-L. Lin A Novel Antiestrogenic Mechanism in Progesterone Receptor-transfected Breast Cancer Cells J. Biol. Chem., April 29, 2005; 280(17): 17480 - 17487. [Abstract] [Full Text] [PDF]

				G. V. Rayasam, C. Elbi, D. A. Walker, R. Wolford, T. M. Fletcher, D. P. Edwards, and G. L. Hager Ligand-Specific Dynamics of the Progesterone Receptor in Living Cells and during Chromatin Remodeling In Vitro Mol. Cell. Biol., March 15, 2005; 25(6): 2406 - 2418. [Abstract] [Full Text] [PDF]

				B. M. Necela and J. A. Cidlowski A Single Amino Acid Change in the First Zinc Finger of the DNA Binding Domain of the Glucocorticoid Receptor Regulates Differential Promoter Selectivity J. Biol. Chem., September 17, 2004; 279(38): 39279 - 39288. [Abstract] [Full Text] [PDF]

				B. Kauppi, C. Jakob, M. Farnegardh, J. Yang, H. Ahola, M. Alarcon, K. Calles, O. Engstrom, J. Harlan, S. Muchmore, et al. The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain: RU-486 INDUCES A TRANSCONFORMATION THAT LEADS TO ACTIVE ANTAGONISM J. Biol. Chem., June 13, 2003; 278(25): 22748 - 22754. [Abstract] [Full Text] [PDF]

				L. Labriola, M. Salatino, C. J. Proietti, A. Pecci, O. A. Coso, A. R. Kornblihtt, E. H. Charreau, and P. V. Elizalde Heregulin Induces Transcriptional Activation of the Progesterone Receptor by a Mechanism That Requires Functional ErbB-2 and Mitogen-Activated Protein Kinase Activation in Breast Cancer Cells Mol. Cell. Biol., February 1, 2003; 23(3): 1095 - 1111. [Abstract] [Full Text]

				J. N. Miner, C. Tyree, J. Hu, E. Berger, K. Marschke, M. Nakane, M. J. Coghlan, D. Clemm, B. Lane, and J. Rosen A Nonsteroidal Glucocorticoid Receptor Antagonist Mol. Endocrinol., January 1, 2003; 17(1): 117 - 127. [Abstract] [Full Text] [PDF]

				S. A. Leonhardt and D. P. Edwards Mechanism of Action of Progesterone Antagonists Experimental Biology and Medicine, December 1, 2002; 227(11): 969 - 980. [Abstract] [Full Text]

				S. E. Wardell, V. Boonyaratanakornkit, J. S. Adelman, A. Aronheim, and D. P. Edwards Jun Dimerization Protein 2 Functions as a Progesterone Receptor N-Terminal Domain Coactivator Mol. Cell. Biol., August 1, 2002; 22(15): 5451 - 5466. [Abstract] [Full Text] [PDF]

				T. Liu and T. F. Ogle Signal Transducer and Activator of Transcription 3 Is Expressed in the Decidualized Mesometrium of Pregnancy and Associates with the Progesterone Receptor Through Protein-Protein Interactions Biol Reprod, July 1, 2002; 67(1): 114 - 118. [Abstract] [Full Text] [PDF]

				Z. Liu, D. Auboeuf, J. Wong, J. D. Chen, S. Y. Tsai, M.-J. Tsai, and B. W. O'Malley Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486 PNAS, June 11, 2002; 99(12): 7940 - 7944. [Abstract] [Full Text] [PDF]

				J.-I. Park, W.-J. Kim, L. Wang, H.-J. Park, J. Lee, J.-H. Park, H.-B. Kwon, A. Tsafriri, and S.-Y. Chun Involvement of progesterone in gonadotrophin-induced pituitary adenylate cyclase-activating polypeptide gene expression in pre-ovulatory follicles of rat ovary Mol. Hum. Reprod., March 1, 2000; 6(3): 238 - 245. [Abstract] [Full Text] [PDF]

				D. L. Clemm, L. Sherman, V. Boonyaratanakornkit, W. T. Schrader, N. L. Weigel, and D. P. Edwards Differential Hormone-Dependent Phosphorylation of Progesterone Receptor A and B Forms Revealed by a Phosphoserine Site-Specific Monoclonal Antibody Mol. Endocrinol., January 1, 2000; 14(1): 52 - 65. [Abstract] [Full Text]

				D. P. Edwards, S. A. Leonhardt, and E. Gass-Handel Novel Mechanisms of Progesterone Antagonists and Progesterone Receptor Reproductive Sciences, January 1, 2000; 7(1_suppl): S22 - S24. [Abstract] [PDF]

				L. V. Nazareth, D. L. Stenoien, W. E. Bingman III, A. J. James, C. Wu, Y. Zhang, D. P. Edwards, M. Mancini, M. Marcelli, D. J. Lamb, et al. A C619Y Mutation in the Human Androgen Receptor Causes Inactivation and Mislocalization of the Receptor with Concomitant Sequestration of SRC-1 (Steroid Receptor Coactivator 1) Mol. Endocrinol., December 1, 1999; 13(12): 2065 - 2075. [Abstract] [Full Text]

				J. R. Lambert and S. K. Nordeen Steroid-selective Initiation of Chromatin Remodeling and Transcriptional Activation of the Mouse Mammary Tumor Virus Promoter Is Controlled by the Site of Promoter Integration J. Biol. Chem., December 4, 1998; 273(49): 32708 - 32714. [Abstract] [Full Text] [PDF]

				S. A. Leonhardt, M. Altmann, and D. P. Edwards Agonist and Antagonists Induce Homodimerization and Mixed Ligand Heterodimerization of Human Progesterone Receptors in Vivo by a Mammalian Two-Hybrid Assay Mol. Endocrinol., December 1, 1998; 12(12): 1914 - 1930. [Abstract] [Full Text]

				C. J. Fryer, H. K. Kinyamu, I. Rogatsky, M. J. Garabedian, and T. K. Archer Selective Activation of the Glucocorticoid Receptor by Steroid Antagonists in Human Breast Cancer and Osteosarcoma Cells J. Biol. Chem., June 2, 2000; 275(23): 17771 - 17777. [Abstract] [Full Text] [PDF]